Important: Human studies used pharmaceutical-grade peptide under clinical supervision, mostly by IV infusion. Kisspeptin-10's half-life is minutes and the axis desensitises to continuous exposure. No approved indication exists.
Overview
Kisspeptin-10 is the biologically active C-terminal decapeptide of kisspeptin, the neuropeptide encoded by the KISS1 gene that sits at the very top of the hypothalamic-pituitary-gonadal (HPG) axis. Loss-of-function mutations in its receptor, GPR54 (now KISS1R), cause hypogonadotropic hypogonadism and absent puberty — the 2003 discovery that made kisspeptin the recognised gatekeeper of reproductive function.
Unlike most research peptides, kisspeptin has a substantial human literature. Intravenous kisspeptin-54 and kisspeptin-10 reliably raise LH, FSH and testosterone in healthy men; kisspeptin-54 has been used as a trigger for egg maturation in IVF; and brain-imaging studies show kisspeptin modulates limbic responses to sexual and emotional stimuli. Kisspeptin-10 is the form most used in the laboratory because it is the shortest fragment that retains full receptor activity.
Mechanism of Action
Kisspeptin-10 is a full agonist at KISS1R (GPR54), a Gαq/11-coupled receptor densely expressed on hypothalamic GnRH neurons. Receptor activation drives phospholipase C, IP3-mediated calcium release and PKC activation, depolarising GnRH neurons and triggering GnRH secretion into the hypophyseal portal system. GnRH then stimulates pituitary gonadotrophs to release LH and FSH, which drive testosterone synthesis in the testes and oestradiol/progesterone production and ovulation in the ovaries.
The response is pulse-shaped: a kisspeptin bolus produces a discrete LH surge, and continuous kisspeptin-10 infusion in men increased LH pulse frequency and raised testosterone. Kisspeptin neurons in the arcuate nucleus (KNDy neurons) are themselves the GnRH pulse generator, integrating oestrogen/testosterone feedback and metabolic inputs (leptin, insulin) — which is why kisspeptin is the molecular link between nutritional state and fertility. Sustained, non-pulsatile exposure can desensitise the axis, an important design consideration in any protocol.
Research Evidence
- Inactivating GPR54/KISS1R mutations cause hypogonadotropic hypogonadism and absent puberty — genetic proof that the kisspeptin system gates human reproduction (Seminara et al., NEJM 2003; PMID 14573733)
- Kisspeptin-54 IV infusion raised LH, FSH and testosterone in healthy men — the first human demonstration of HPG-axis activation (Dhillo et al., JCEM 2005; PMID 16174713)
- Kisspeptin-10 boluses potently evoke LH secretion in men; 22.5-hour infusion at 4 µg/kg/h raised mean LH from 5.4 to 20.8 IU/L and testosterone from 16.6 to 24.0 nmol/L (George et al., JCEM 2011; PMID 21632807)
- A single kisspeptin-54 injection triggered egg maturation in women undergoing IVF, with live births — a therapeutic proof-of-concept in reproductive medicine (Jayasena et al., JCI 2014)
- Kisspeptin administration enhanced limbic brain responses to sexual and couple-bonding images in healthy men on fMRI (Comninos et al., JCI 2017)
- Kisspeptin-10 stimulated testosterone and LH in men with type 2 diabetes and mild biochemical hypogonadism (George et al., 2013; PMID 23153270)
Bottom line: The reproductive-axis evidence is real and human. Claims about fat loss, metabolism or muscle are not supported by any study. The peptide lasts only minutes in blood and the axis can desensitise to continuous exposure. Research-only; not FDA-approved.
Evidence & References
The full compound profile lists the evidence level, the studies behind each claim with PubMed links, and the adverse-effect record. Compound Review does not publish dosing protocols.
Sourcing & Quality
Kisspeptin-10 is available from Purgo Labs with third-party COA verification and research-grade purity standards. View Kisspeptin-10 at Purgo Labs.